Seroatlas · Human Serome Atlas

PRUNE2

Protein prune homolog 2

Also known as: A214N16.3, bA214N16.3, BMCC1, BNIPXL, C9orf65, KIAA0367, PRUN2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q8WUY3
Gene
PRUNE2
Ensembl
ENSG00000106772
Chromosome
9
Canonical length
3088 aa
Protein class
Predicted intracellular proteins, Predicted membrane proteins
Subcellular location
Cytosol

OverviewNCBI Gene

The protein encoded by this gene belongs to the B-cell CLL/lymphoma 2 and adenovirus E1B 19 kDa interacting family, whose members play roles in many cellular processes including apotosis, cell transformation, and synaptic function. Several functions for this protein have been demonstrated including suppression of Ras homolog family member A activity, which results in reduced stress fiber formation and suppression of oncogenic cellular transformation. A high molecular weight isoform of this protein has also been shown to colocalize with Adaptor protein complex 2, beta-Adaptin and endodermal markers, suggesting an involvement in post-endocytic trafficking. In prostate cancer cells, this gene acts as a tumor suppressor and its expression is regulated by prostate cancer antigen 3, a non-protein coding gene on the opposite DNA strand in an intron of this gene. Prostate cancer antigen 3 regulates levels of this gene through formation of a double-stranded RNA that undergoes adenosine deaminase actin on RNA-dependent adenosine-to-inosine RNA editing. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015]

Canonical amino-acid sequenceUniProt

3088 residues, UniProt reviewed canonical sequence.

>Q8WUY3|PRUNE2
     1  MEEFLQRAKS KLNRSKRLEK VHVVIGPKSC DLDSLISTFT YAYFLDKVSP PGVLCLPVLN
    61  IPRTEFNYFT ETRFILEELN ISESFHIFRD EINLHQLNDE GKLSITLVGS SVLASEDKTL
   121  ESAVVKVINP VEQSDANVEF RESSSSLVLK EILQEAPELI TEQLAHRLRG SILFKWMTME
   181  SEKISEKQEE ILSILEEKFP NLPPREDIIN VLQETQFSAQ GLSIEQTMLK DLKELSDGEI
   241  KVAISTVSMN LENCLFHSNI TSDLKAFTDK FGFDVLILFS SYLSEEQQPR RQIAVYSENM
   301  ELCSQICCEL EECQNPCLEL EPFDCGCDEI LVYQQEDPSV TCDQVVLVVK EVINRRCPEM
   361  VSNSRTSSTE AVAGSAPLSQ GSSGIMELYG SDIEPQPSSV NFIENPPDLN DSNQAQVDAN
   421  VDLVSPDSGL ATIRSSRSSK ESSVFLSDDS PVGEGAGPHH TLLPGLDSYS PIPEGAVAEE
   481  HAWSGEHGEH FDLFNFDPAP MASGQSQQSS HSADYSPADD FFPNSDLSEG QLPAGPEGLD
   541  GMGTNMSNYS SSSLLSGAGK DSLVEHDEEF VQRQDSPRDN SERNLSLTDF VGDESPSPER
   601  LKNTGKRIPP TPMNSLVESS PSTEEPASLY TEDMTQKATD TGHMGPPQTH ARCSSWWGGL
   661  EIDSKNIADA WSSSEQESVF QSPESWKEHK PSSIDRRASD SVFQPKSLEF TKSGPWESEF
   721  GQPELGSNDI QDKNEESLPF QNLPMEKSPL PNTSPQGTNH LIEDFASLWH SGRSPTAMPE
   781  PWGNPTDDGE PAAVAPFPAW SAFGKEDHDE ALKNTWNLHP TSSKTPSVRD PNEWAMAKSG
   841  FAFSSSELLD NSPSEINNEA APEIWGKKNN DSRDHIFAPG NPSSDLDHTW TNSKPPKEDQ
   901  NGLVDPKTRG KVYEKVDSWN LFEENMKKGG SDVLVPWEDS FLSYKCSDYS ASNLGEDSVP
   961  SPLDTNYSTS DSYTSPTFAG DEKETEHKPF AKEEGFESKD GNSTAEETDI PPQSLQQSSR
  1021  NRISSGPGNL DMWASPHTDN SSEINTTHNL DENELKTEHT DGKNISMEDD VGESSQSSYD
  1081  DPSMMQLYNE TNRQLTLLHS STNSRQTAPD SLDLWNRVIL EDTQSTATIS DMDNDLDWDD
  1141  CSGGAAIPSD GQTEGYMAEG SEPETRFTVR QLEPWGLEYQ EANQVDWELP ASDEHTKDSA
  1201  PSEHHTLNEK SGQLIANSIW DSVMRDKDMS SFMLPGSSHI TDSEQRELPP EIPSHSANVK
  1261  DTHSPDAPAA SGTSESEALI SHLDKQDTER ETLQSDAASL ATRLENPGYF PHPDPWKGHG
  1321  DGQSESEKEA QGATDRGHLD EEEVIASGVE NASGISEKGQ SDQELSSLVA SEHQEICIKS
  1381  GKISSLAVTF SPQTEEPEEV LEYEEGSYNL DSRDVQTGMS ADNLQPKDTH EKHLMSQRNS
  1441  GETTETSDGM NFTKYVSVPE KDLEKTEECN FLEPENVGGG PPHRVPRSLD FGDVPIDSDV
  1501  HVSSTCSEIT KNLDVKGSEN SLPGAGSSGN FDRDTISSEY THSSASSPEL NDSSVALSSW
  1561  GQQPSSGYQE ENQGNWSEQN HQESELITTD GQVEIVTKVK DLEKNRINEF EKSFDRKTPT
  1621  FLEIWNDSVD GDSFSSLSSP ETGKYSEHSG THQESNLIAS YQEKNEHDIS ATVQPEDARV
  1681  ISTSSGSDDD SVGGEESIEE EIQVANCHVA EDESRAWDSL NESNKFLVTA DPKSENIYDY
  1741  LDSSEPAENE NKSNPFCDNQ QSSPDPWTFS PLTETEMQIT AVEKEKRSSP ETGTTGDVAW
  1801  QISPKASFPK NEDNSQLEML GFSADSTEWW KASPQEGRLI ESPFERELSD SSGVLEINSS
  1861  VHQNASPWGV PVQGDIEPVE THYTNPFSDN HQSPFLEGNG KNSHEQLWNI QPRQPDPDAD
  1921  KFSQLVKLDQ IKEKDSREQT FVSAAGDELT PETPTQEQCQ DTMLPVCDHP DTAFTHAEEN
  1981  SCVTSNVSTN EGQETNQWEQ EKSYLGEMTN SSIATENFPA VSSPTQLIMK PGSEWDGSTP
  2041  SEDSRGTFVP DILHGNFQEG GQLASAAPDL WIDAKKPFSL KADGENPDIL THCEHDSNSQ
  2101  ASDSPDICHD SEAKQETEKH LSACMGPEVE SSELCLTEPE IDEEPIYEPG REFVPSNAEL
  2161  DSENATVLPP IGYQADIKGS SQPASHKGSP EPSEINGDNS TGLQVSEKGA SPDMAPILEP
  2221  VDRRIPRIEN VATSIFVTHQ EPTPEGDGSW ISDSFSPESQ PGARALFDGD PHLSTENPAL
  2281  VPDALLASDT CLDISEAAFD HSFSDASGLN TSTGTIDDMS KLTLSEGHPE TPVDGDLGKQ
  2341  DICSSEASWG DFEYDVMGQN IDEDLLREPE HFLYGGDPPL EEDSLKQSLA PYTPPFDLSY
  2401  LTEPAQSAET IEEAGSPEDE SLGCRAAEIV LSALPDRRSE GNQAETKNRL PGSQLAVLHI
  2461  REDPESVYLP VGAGSNILSP SNVDWEVETD NSDLPAGGDI GPPNGASKEI SELEEEKTIP
  2521  TKEPEQIKSE YKEERCTEKN EDRHALHMDY ILVNREENSH SKPETCEERE SIAELELYVG
  2581  SKETGLQGTQ LASFPDTCQP ASLNERKGLS AEKMSSKSDT RSSFESPAQD QSWMFLGHSE
  2641  VGDPSLDARD SGPGWSGKTV EPFSELGLGE GPQLQILEEM KPLESLALEE ASGPVSQSQK
  2701  SKSRGRAGPD AVTLQAVTHD NEWEMLSPQP VQKNMIPDTE MEEETEFLEL GTRISRPNGL
  2761  LSEDVGMDIP FEEGVLSPSA ADMRPEPPNS LDLNDTHPRR IKLTAPNINL SLDQSEGSIL
  2821  SDDNLDSPDE IDINVDELDT PDEADSFEYT GHDPTANKDS GQESESIPEY TAEEEREDNR
  2881  LWRTVVIGEQ EQRIDMKVIE PYRRVISHGG YYGDGLNAII VFAACFLPDS SRADYHYVME
  2941  NLFLYVISTL ELMVAEDYMI VYLNGATPRR RMPGLGWMKK CYQMIDRRLR KNLKSFIIVH
  3001  PSWFIRTILA VTRPFISSKF SSKIKYVNSL SELSGLIPMD CIHIPESIIK LDEELREASE
  3061  AAKTSCLYND PEMSSMEKDI DLKLKEKP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRUNE2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0
Highest tissue expression
102 nTPM

Expression across tissuesHPA

Tissue

  • blood vessel: 102 nTPM
  • colon: 102 nTPM
  • cerebellum: 82 nTPM
  • urinary bladder: 66 nTPM
  • seminal vesicle: 60 nTPM
  • tongue: 53 nTPM

Single-cell type

  • oligodendrocytes: 1,227 nCPM
  • retinal ganglion cells: 1,136 nCPM
  • adrenal medulla cells: 1,074 nCPM
  • smooth muscle cells: 1,016 nCPM
  • gonadotrophs: 704 nCPM
  • proximal tubule cells: 704 nCPM

Immune cell

  • classical monocyte: 0.5 nTPM
  • intermediate monocyte: 0.5 nTPM
  • myeloid DC: 0.4 nTPM
  • neutrophil: 0.4 nTPM
  • basophil: 0.3 nTPM
  • NK-cell: 0.3 nTPM

Brain region

  • white matter: 273 nTPM
  • medulla oblongata: 223 nTPM
  • basal ganglia: 201 nTPM
  • pons: 196 nTPM
  • midbrain: 143 nTPM
  • thalamus: 142 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PRUNE2.

Disease | ImmuneIEDB

Conditions an epitope on PRUNE2 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.72
gnomAD pLI
0
gnomAD missense Z
0.54
DepMap mean gene effect
-0.03
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRUNE2 as an antibody target. Whether an autoantibody or antibody against PRUNE2 could matter depends on whether native PRUNE2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRUNE2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRUNE2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PRUNE2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...